Evaluating 3 Types of Targeted Therapies for Triple-Negative Breast Cancer
Aditya Bardia, MBBS, MPH, discusses the development of targeted therapies for patients with triple-negative breast cancer. He says these approaches can be divided into 3 different categories.
Aditya Bardia, MBBS, MPH, a breast medical oncologist at Massachusetts General Hospital and Harvard Medical School, discusses the development of targeted therapies for patients with triple-negative breast cancer (TNBC). He says these approaches can be divided into 3 different categories.
The first category would be targeting oncogenes. An example of this would be the use of PARP inhibitors. Second, ongoing trials are also looking at intercellular signaling pathways, says Bardia.
Breast Cancer Leans into the Decade of Antibody-Drug Conjugates, Experts Discuss
September 25th 2020In season 1, episode 3 of Targeted Talks, the importance of precision medicine in breast cancer, and how that vitally differs in community oncology compared with academic settings, is the topic of discussion.
Listen
Neoadjuvant and Adjuvant Pembrolizumab Extends Survival in Early-Stage TNBC
September 15th 2024In KEYNOTE-522, treatment with neoadjuvant pembrolizumab and chemotherapy, followed by adjuvant pembrolizumab, led to improvements in overall survival among patients with triple-negative breast cancer.
Read More
